ZANTAC IN PLASTIC CONTAINER Drug Patent Profile

When do Zantac In Plastic Container patents expire, and what generic alternatives are available?

Zantac In Plastic Container is a drug marketed by Pai Holdings Pharm and is included in one NDA.

The generic ingredient in ZANTAC IN PLASTIC CONTAINER is ranitidine hydrochloride. There are forty-three drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the ranitidine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zantac In Plastic Container

A generic version of ZANTAC IN PLASTIC CONTAINER was approved as ranitidine hydrochloride by SANDOZ on August 29^th, 1997.

Summary for ZANTAC IN PLASTIC CONTAINER

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	77
Clinical Trials:	22
Patent Applications:	4
DailyMed Link:	ZANTAC IN PLASTIC CONTAINER at DailyMed

Recent Clinical Trials for ZANTAC IN PLASTIC CONTAINER

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Food and Drug Administration (FDA)	Phase 1
Spaulding Clinical Research LLC	Phase 1
Lisa Barrett	Phase 4

See all ZANTAC IN PLASTIC CONTAINER clinical trials

US Patents and Regulatory Information for ZANTAC IN PLASTIC CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pai Holdings Pharm	ZANTAC IN PLASTIC CONTAINER	ranitidine hydrochloride	INJECTABLE;INJECTION	019593-002	Sep 27, 1991		DISCN	No	No
Pai Holdings Pharm	ZANTAC IN PLASTIC CONTAINER	ranitidine hydrochloride	INJECTABLE;INJECTION	019593-001	Dec 17, 1986		DISCN	No	No

Expired US Patents for ZANTAC IN PLASTIC CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pai Holdings Pharm	ZANTAC IN PLASTIC CONTAINER	ranitidine hydrochloride	INJECTABLE;INJECTION	019593-001	Dec 17, 1986
Pai Holdings Pharm	ZANTAC IN PLASTIC CONTAINER	ranitidine hydrochloride	INJECTABLE;INJECTION	019593-002	Sep 27, 1991
Pai Holdings Pharm	ZANTAC IN PLASTIC CONTAINER	ranitidine hydrochloride	INJECTABLE;INJECTION	019593-001	Dec 17, 1986
Pai Holdings Pharm	ZANTAC IN PLASTIC CONTAINER	ranitidine hydrochloride	INJECTABLE;INJECTION	019593-002	Sep 27, 1991

International Patents for ZANTAC IN PLASTIC CONTAINER

See the table below for patents covering ZANTAC IN PLASTIC CONTAINER around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	A422281
Denmark	237884
South Korea	830007070
Germany	3417606	Pharmazeutische Zubereitung von Ranitidin

Market Dynamics and Financial Trajectory for Zantac in Plastic Containers

Last updated: July 27, 2025

---

Introduction

Zantac, generically known as ranitidine, was once a leading medication for the treatment of gastrointestinal conditions such as gastroesophageal reflux disease (GERD) and peptic ulcers. Its market prominence curtailed significantly following recalls linked to contamination concerns, notably NDMA (N-Nitrosodimethylamine) impurity. Analyzing the current market dynamics and financial projections for Zantac, particularly in plastic container formulations, reveals shifts driven by regulatory actions, consumer preferences, litigation impacts, and manufacturing innovations.

---

Historical Context and Market Decline

Zantac’s decline began in 2019 when the U.S. Food and Drug Administration (FDA) issued a recall of ranitidine products due to NDMA impurity, a probable carcinogen (FDA, 2019). Major pharmaceutical companies, including Sanofi and GlaxoSmithKline, withdrew ranitidine from shelves. The recall led to a near cessation of traditional Zantac sales globally, creating a substantial void for anti-ulcer medications.

---

Current Market Dynamics

1. Regulatory Environment

Post-recall, regulatory agencies worldwide intensified scrutiny on ranitidine, categorizing it as an unsafe drug. The FDA’s stance catalyzed global regulatory discontinuation, prompting the pharmaceutical industry to shift focus toward alternative medications such as proton pump inhibitors (PPIs) (FDA, 2019). The regulatory stance has substantially suppressed the traditional Zantac market, compelling companies to seek new formulations or rebrand in compliance with safety standards.

2. Product Formulation and Packaging

The initial form—tablet and liquid in glass or plastic bottles—has faced obsolescence due to safety concerns related to packaging. The pharmaceutical industry has pivoted toward safer containers, with plastic blister packs and sealed plastic bottles being the primary alternatives. These containers (plastic bottles, in particular) offer advantages such as durability, ease of use, and conservation of medication efficacy. The choice of plastic container type directly influences distribution, shelf-life, and adherence.

3. Consumer and Healthcare Provider Confidence

Consumer trust in Zantac collapsed after the recall, with many switching to alternative therapies. Healthcare providers, wary of liability and safety records, discontinued prescribing ranitidine. The market is now largely led by alternative drugs like omeprazole and esomeprazole, reducing Zantac’s market share to niche or generic segments where residual demand exists for specific formulations or in regions with fewer regulatory restrictions.

4. Litigation and Legal Developments

Extensive litigation related to NDMA contamination, including lawsuits claiming damages from exposure, has significantly impacted Zantac’s financial landscape. Several legal actions, particularly in the U.S., have resulted in multi-billion-dollar settlements (Reuters, 2022). These legal risks have diminished manufacturer incentives to produce or market Zantac actively, particularly in any new plastic container formulations, unless in limited or controlled markets.

---

Financial Trajectory

1. Revenue Impact and Market Valuation

The collapse of Zantac’s revenue post-recall is well-documented. In 2019, Sanofi’s Zantac franchise accounted for approximately €1.2 billion in annual revenue (Sanofi Annual Report, 2018). Following recalls, global sales plummeted by over 95% within a year. The revenue in markets where formulations persist in restricted forms has plateaued or declined further due to diminishing consumer confidence.

2. Current Market Segments

• Generic Zantac in Niche Markets: Residual sales occur in regions with limited enforcement of recall directives, with formulations primarily in plastic containers—small bottles for compounded or compounded-like use.
• Repurposed or Rebranded Formulations: Some manufacturers have attempted to reintroduce ranitidine or similar molecules under different brand names or in reformulated versions with enhanced testing for NDMA. These are often packaged in modern plastic bottles or containers compliant with safety standards, yet sales remain subdued.

3. Future Outlook and Investment Risks

Given regulatory pressures and litigation, long-term financial prospects for Zantac are bleak. Most companies have shifted R&D investments toward safer alternatives, and marginalization of ranitidine in the pharmaceutical pipeline is evident. Investment in Zantac manufacturing, especially in plastic containers, is increasingly viewed as high-risk with limited upside.

---

Market Opportunities and Challenges

Opportunities

• Niche Markets and Compounded Drugs: Small-scale formulations in plastic containers for specialized use or compounded pharmacies could sustain marginal sales.
• Regulatory-Approved Reformulations: If manufacturers develop first-to-market, NDMA-free versions of ranitidine, they could tap into residual demand under strict regulatory compliance, with plastic containers facilitating easy dispensing.

Challenges

• Legal and Regulatory Barriers: Ongoing lawsuits and strict bans severely limit market entry.
• Consumer Perception: Trust deficit hampers demand.
• Supply Chain Constraints: Safety packaging and rigorous testing escalate costs, impacting profitability.

---

Conclusion: Evolution of the Zantac Market

The trajectory of Zantac, especially in plastic containers, is marked by drastic decline and regulatory constraints. Although residual demand exists in limited niches, the overall market is contracting, influenced by safety concerns, legal risks, and shifting therapeutic preferences. Future financial prospects are confined to specialized formulations, with companies leaning toward innovation in packaging and compliance to sustain minimal revenues. The overarching trend underscores the importance of safety, stringent regulation, and consumer health consciousness shaping pharmaceutical market dynamics.

---

Key Takeaways

• Regulatory environments have critically curtailed Zantac's market, emphasizing safety and compliance, especially concerning NDMA contamination.
• Plastic containers remain relevant primarily within niche or compounded formulations, but large-scale manufacturing and sales are unlikely to rebound significantly.
• Legal liabilities continue to suppress Zantac's market viability, with extensive litigation deterring investment unless reformulations free from NDMA are developed.
• Alternative therapies dominate the market, reducing Zantac's role primarily to residual or specialized segments.
• Innovation in formulation and packaging could sustain minimal demand, but profitability remains uncertain amid evolving regulatory and safety standards.

---

FAQs

1. Will Zantac return to the mainstream market?
Unlikely in the near term. Regulatory bans, safety concerns, and legal liabilities have effectively eliminated its mainstream presence. Any re-entry would require reformulation free from NDMA, extensive testing, and regulatory approval.

2. Are there safe plastic containers for Zantac formulations?
Yes, modern pharmaceutical packaging utilizes validated plastic containers that meet safety and stability standards. However, their use is confined to niche or compounded formulations due to ongoing safety concerns.

3. What alternative drugs have replaced Zantac?
Proton pump inhibitors (PPIs), such as omeprazole, esomeprazole, and lansoprazole, now dominate the market for similar indications, offering safer and more effective options.

4. How significant are legal liabilities in shaping Zantac's future?
Extremely significant. Litigation costs and potential settlements have discouraged investment, led to withdrawal from markets, and effectively limited new formulations’ development.

5. What is the outlook for companies holding residual Zantac patents or formulations?
Most are phasing out manufacturing and marketing. Remaining operations are likely small-scale and geared toward specialized use or reformulations that meet safety standards, with uncertain financial viability.

---

Sources:
[1] FDA, 2019. "Recall of Ranitidine (Zantac) Due to NDMA Contamination," Food and Drug Administration.
[2] Reuters, 2022. “Major Zantac Litigation and Settlement Developments.”
[3] Sanofi Annual Report, 2018. “Financial Performance of Zantac Franchise.”